Marksans Pharma share news, announcements and annual reports
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Marksans Pharma Limited · Formerly Tasc Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Jan 2002 on NSE
Last close ₹306.20down ₹9.15 (2.90%)BSE ₹306.65
Share price at the NSE close on 30 Oct 2026. Previous close ₹315.35.
30 Oct: open ₹317.00, high ₹317.35, low ₹304.90
52-week range of traded prices to 30 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13,876 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.59
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 12,10,63344.3% delivered
Marksans Pharma board meetings
119 filed, newest first. Page 2 of 3.
May 2019
Feb 2019
Jan 2019
31 Jan · Board meeting
Nov 2018
Aug 2018
25 Aug · Board meeting
Jul 2018
27 Jul · Board meeting
May 2018
Feb 2018
12 Feb · Board meeting
Nov 2017
Aug 2017
May 2017
Jan 2017
Nov 2016
Aug 2016
May 2016
Jan 2016
Nov 2015
Jul 2015
May 2015
Jan 2015
29 Jan · Board meeting
Inter alia to consider and approve Unaudited Financial Results for the Quarter ended 31st December, 2014.
Oct 2014
20 Oct · Board meeting
Inter alia, to consider and approve Unaudited Financial Results of the Company for the Quarter ended September 30, 2014.
Aug 2014
May 2014
Jan 2014
20 Jan · Board meeting
To consider and approve Unaudited Financial Results of the Company for the quarter ended December 31, 2013.
Oct 2013
21 Oct · Board meeting
To consider and approve Unaudited Financial Results of the Company for the Quarter ended September 30, 2013.
Jul 2013
22 Jul · Board meeting
To consider and approve Unaudited Financial Results of the Company for the Quarter ended June 30, 2013.
May 2013
20 May · Board meeting
To consider and approve Annual Audited Financial Results of the Company for the financial year ended on March 31, 2013.
Feb 2013
5 Feb · Board meeting
To consider and approve Unaudited Financial Results of the Company for the Quarter ended on December 31, 2012.
Dec 2012
17 Dec · Board meeting
10 Dec · Board meeting
To consider conversion of warrants and issue and allot in lieu thereof 1,75,00,000 Equity Shares of Re.1/- each to Mr. Mark Saldanha,Promoter of the Company on preferential allotment basis.
Nov 2012
1 Nov · Board meeting
To consider and approve Unaudited Financial Results of the Company for the Quarter ended on September 30, 2012.
Aug 2012
3 Aug · Board meeting
To consider and approve Unaudited Financial Results of the Company for the Quarter ended June 30, 2012.
May 2012
18 May · Board meeting
To consider and approve Annual Audited Financial Results for the financial year ended on March 31, 2012.
Feb 2012
1 Feb · Board meeting
To consider and approve Unaudited Financial Results for the Quarter ended on December 31, 2011.
Nov 2011
2 Nov · Board meeting
To consider and approve Unaudited Financial Results for the Quarter ended on September 30, 2011.
Aug 2011
26 Aug · Board meeting
In order to strengthen the capital base of the Company, the Board of Directors of the Company at its meeting held August 26, 2011, has proposed to issue, subject to the approval of the shareholders and the regulatory authority as applicable 1,75,00,000 (One crore seventy five lacs only) warrants convertible into equal numbers of equity shares of Re. 1/- each to the Promoters of the Company under private placement basis at such price and under the terms and conditions in accordance with Chapter VII of the SEBI (ICDR) Regulations, 2009 as in force.2 Aug · Board meeting
To consider and approve Unaudited Financial Results for the quarter ended June 30, 2011.
Jun 2011
20 Jun · Board meeting
To consider and approve Consolidated Annual Audited Financial Results of the Company for the Financial Year ended on March 31, 2011.
May 2011
18 May · Board meeting
Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on May 20, 2011 to consider and approve Audited Financial Results of the Company for the Financial Year ended on March 31, 2011. The Company has now informed the Exchange that the aforesaid meeting of the Board of Directors of the Company is rescheduled to be held on May 28, 2011 (instead May 20,2011 as intimated earlier) to consider and approve Audited Financial Results of the Company for the Financial Year ended on March 31, 2011.Not held on this date
12 May · Board meeting
To consider and approve Audited Financial Results of the Company for the Financial Year ended on March 31, 2011.
Feb 2011
7 Feb · Board meeting
To consider and approve Unaudited Financial Results for the Quarter ended on December 31, 2010.
Nov 2010
3 Nov · Board meeting
To consider and approve Unaudited Financial Results for the Quarter ended on September 30, 2010.
Jul 2010
30 Jul · Board meeting
To consider and approve :- (1) Annual Audited Financial Results for the Year ended March 31, 2010, and (2) Unaudited Financial Results for the Quarter ended on June 30, 2010.
Apr 2010
19 Apr · Board meeting
To consider and approve Unaudited Financial Results for the quarter ended March 31, 2010.
Jan 2010
15 Jan · Board meeting
Meeting on 29 Jan 2010: “Unaudited Financial Results for the qtr ended Dec 31, 2009”
Dec 2009
29 Dec · Board meeting
Board of Directors of the Company, at its meeting held on December 29, 2009, has decided to conduct postal ballot to seek approval of the members of the Company: (1) To sell/lease/dispose the Active Pharmaceutical Ingredient (API) plants of the Company located at Plot No. A88 & D10, Kurkumbh, MIDC, Pune, by way of an Ordinary Resolution under Section 293(1)(a) of the Companies Act, 1956, and; (2) To raise capital through issue of equity shares and/or equity shares through depository receipts and/or foreign currency convertible bonds and/or any other convertible bonds/securities upto an amount not exceeding USD 125 Million by way of a Special Resolution under Section 81(1A) of the Companies Act, 1956.28 Dec · Board meeting
To consider and approve conduct of postal ballot to seek approval of the members of the Company: (1) To sell/lease/dispose the Active Pharmaceutical Ingredient (API) plants of the Company located at Plot No. A88 & D10, Kurkumbh, MIDC, Pune, by way of an Ordinary Resolution under Section 293(1)(a) of the Companies Act, 1956, and; (2) To raise capital through issue of equity shares and/or equity shares through depository receipts and/or foreign currency convertible bonds and/or any other convertible bonds/securities upto an amount not exceeding USD 125 Million by way of a Special Resolution under Section 81(1A) of the Companies Act, 1956.
Oct 2009
9 Oct · Board meeting
Meeting on 30 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Jul 2009
20 Jul · Board meeting
Meeting on 31 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”